Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
Transcenta Holding Limited announced interim results for the six months ended June 30, 2024, highlighting clinical progress with osemitamab (TST001) in G/GEJ cancer, safety and PK data consistency in U.S. and Chinese patients, collaboration with Agilent for Claudin18.2 CDx Assay, and positive results from blosozumab (TST002) SAD study for osteoporosis. The company also completed enrollment for the FIH trial of anti-GREMLIN-1 antibody TST003 and made advancements in bioprocessing technology.
Reference News
Transcenta Holding Limited announced interim results for the six months ended June 30, 2024, highlighting clinical progress with osemitamab (TST001) in G/GEJ cancer, safety and PK data consistency in U.S. and Chinese patients, collaboration with Agilent for Claudin18.2 CDx Assay, and positive results from blosozumab (TST002) SAD study for osteoporosis. The company also completed enrollment for the FIH trial of anti-GREMLIN-1 antibody TST003 and made advancements in bioprocessing technology.